Home » Topics » BioWorld Science

BioWorld Science
RSS

Trillium initiates dosing of patients with TP53-mutated AML in phase Ib/II study of TTI-622

Aug. 10, 2021

Phase II MERIT study of AXS-05 achieves primary and key secondary endpoints

Aug. 10, 2021

Gruenenthal divulges glucocorticoid receptor modulators

Aug. 10, 2021

New PIN1 inhibitors discovered at Pimedbio, DGMIF

Aug. 10, 2021

Shanghai Hengrui Pharmaceutical, Jiangsu Hengrui Medicine patent ATR kinase inhibitors

Aug. 10, 2021

Korea Institute of Science and Technology identifies TNK2/MAP4K2 inhibitors

Aug. 10, 2021

First patient dosed in phase Ib/II study of AVB-500 in pancreatic adenocarcinoma

Aug. 10, 2021

TRACON presents safety data review results for ENVASARC pivotal trial of envafolimab

Aug. 10, 2021

Allena initiates two phase II trials of its engineered urate oxidase, ALLN-346

Aug. 10, 2021

Response rate shows potential of ficlatuzumab with chemotherapy in treating AML

Aug. 9, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...